<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110573</url>
  </required_header>
  <id_info>
    <org_study_id>B3962020000032</org_study_id>
    <nct_id>NCT05110573</nct_id>
  </id_info>
  <brief_title>Single-centre Propensity Score-matched Comparison of Laparoscopic Versus Open Pancreatoduodenectomy</brief_title>
  <acronym>PSMLOPD</acronym>
  <official_title>Morbidity and Survival After Minimally Invasive Versus Open Pancreatoduodenectomy: Propensity Score Matched Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital Groeninge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital Groeninge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Minimally invasive pancreatoduodenectomy is increasingly performed. However, technical&#xD;
      challenges and a perceived higher risk of complications has hindered wide adoption of a&#xD;
      minimally invasive approach.&#xD;
&#xD;
      This is a retrospective comparison of a prospectively kept database. The investigators&#xD;
      compared surgical outcomes and survival after laparoscopic (LPD) versus open&#xD;
      pancreatoduodenectomy (OPD). In order to reduce the effect of bias and confounding, baseline&#xD;
      characteristics of both groups were matched using propensity score matching.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All pancreatoduodenectomies were retrieved from a prospectively kept database and&#xD;
      retrospectively analysed. All procedures were performed in a single supra-regional Belgian&#xD;
      centre.&#xD;
&#xD;
      The primary endpoint was the major complication rate, defined by a Clavien-Dindo morbidity&#xD;
      classification grade IIIa or higher [11]. Secondary endpoints were 90-day mortality rate,&#xD;
      length of hospital stay, operative time, blood loss, transfusion requirements and specific&#xD;
      pancreatic complications (pancreatic fistula, haemorrhage, and delayed gastric emptying). In&#xD;
      addition, overall survival (OS) and disease-free survival (DFS) were analysed in the&#xD;
      subgroups of cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2000</start_date>
  <completion_date type="Actual">March 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major complication rate</measure>
    <time_frame>90 days postoperative</time_frame>
    <description>Complications classified as morbidity classification 3a or greater (Clavien-Dindo)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative outcomes</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Operative time (min), blood transfusion requirements, estimated blood loss (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term postoperative outcomes</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Hospital stay (days), drain in situ (days), ICU stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>90 days</time_frame>
    <description>All complications classified as morbidity classification 3a or greater (Clavien-Dindo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatectomy-specific complications</measure>
    <time_frame>90 days</time_frame>
    <description>Postoperative pancreatic fistula, Post-pancreatectomy haemorrhage, delayed gastric emptying, as defined by the respective ISGPS classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival and disease-free survival</measure>
    <time_frame>Up to 20 years</time_frame>
    <description>The Kaplan-Meier method was used for estimation of survival and compared between subgroups of cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncological outcomes</measure>
    <time_frame>Up to 20 years</time_frame>
    <description>Analysis of resection specimen following contemporary pathlogy guidelines and defined by TNM staging system of pancreatic cancer by AJCC/UICC.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">172</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Laparoscopic pancreatoduodenectomy</arm_group_label>
    <description>Cohort of patients that underwent a Whipple-procedure through a laparoscopic approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open pancreatoduodenectomy</arm_group_label>
    <description>Cohort of patients that underwent a Whipple-procedure through a traditional open approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pancreatoduodenectomy</intervention_name>
    <description>Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic</description>
    <arm_group_label>Laparoscopic pancreatoduodenectomy</arm_group_label>
    <arm_group_label>Open pancreatoduodenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Indications for surgery were benign or malignant lesions of the pancreatic head or&#xD;
        peri-ampullary organs. All patients of â‰¥18 years old diagnosed with suspicious lesions&#xD;
        located in the pancreas, ampulla, duodenum or distal bile duct were presented at the&#xD;
        multidisciplinary oncological team. In case of biopsy-proven malignancy or clinical and&#xD;
        radiological suspicion without confirmed malignancy, surgical resection was considered in&#xD;
        accordance with contemporary guidelines&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of lesion of pancreatic head or peri-ampullary organs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathieu D'Hondt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1. Department of Digestive and Hepatobiliary/Pancreatic Surgery AZ Groeninge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital Groeninge</investigator_affiliation>
    <investigator_full_name>Dr. M. D'hondt</investigator_full_name>
    <investigator_title>Dr. Mathieu D'Hondt, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>pancreatoduodenectomy</keyword>
  <keyword>minimally-invasive surgery</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>chronic pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

